Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00243
|
|||||
| Drug Name |
Mycophenolate mofetil
|
|||||
| Synonyms |
2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate; 2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate; 2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate; 2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate;4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E); CellCept; CellCept, RS 61443, TM-MMF, Mycophenolate mofetil; Cellcept (TN); ME-MPA; MMF; MMF CellCept(TM); Munoloc; Mycophenolate mofetil (JAN/USAN); Mycophenolic acid morpholinoethyl ester; Mycophenylate mofetil; R-99; RS 61443; RS-61443; RS-61443-190; TM-MMF
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Pemphigus vulgaris [ICD11:EB40.0] | Approved | [1] | |||
| Therapeutic Class |
Immunosuppressive Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C23H31NO7
|
|||||
| Canonical SMILES |
CC1=C2COC(=O)C2=C(C(=C1OC)CC=C(C)CCC(=O)OCCN3CCOCC3)O
|
|||||
| InChI |
InChI=1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+
|
|||||
| InChIKey |
RTGDFNSFWBGLEC-SYZQJQIISA-N
|
|||||
| CAS Number |
CAS 128794-94-5
|
|||||
| Pharmaceutical Properties | Molecular Weight | 433.5 | Topological Polar Surface Area | 94.5 | ||
| Heavy Atom Count | 31 | Rotatable Bond Count | 10 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 8 | |||
| XLogP |
3.2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10110
,103524891
,103831140
,104253178
,113854519
,117622077
,118053002
,12014254
,124757298
,125164102
,125275456
,126592936
,126621236
,126622394
,126651543
,126669998
,126682700
,131295332
,131297141
,132003527
,134338068
,134339833
,135016986
,135039794
,136949095
,137004579
,142385187
,144075766
,14758955
,29215410
,39289999
,46505626
,48416299
,49830660
,49976609
,50064190
,537396
,56310881
,56312885
,57358003
,62129612
,623972
,77319688
,7847817
,80954261
,8616507
,92308999
,92718908
,93619754
,96099842
|
|||||
| ChEBI ID |
ChEBI:93612
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [3] | ||
| OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [3] | ||
| OATP1B3 | Transporter Info | Organic anion transporting polypeptide 1B3 | Substrate | [3] | ||
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | ||
| References | ||||||
| 1 | Mycophenolic acid was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther Drug Monit. 2008 Oct;30(5):559-64. | |||||
| 3 | Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.